{"public_id":"co_b4c7d87f2675e804735f74e2795a33e3","status":"active","merged_into_public_id":null,"resolved_public_id":"co_b4c7d87f2675e804735f74e2795a33e3","name":"adjudicated cardiovascular event rates","description":"Blinded, adjudicated rates of cardiovascular adverse events and death used in safety assessment.","aliases":["APTC CV event rates"],"types":["safety outcome"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":6351267,"title":"The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial","citation_count":519,"url":"https://sah.borca.ai/papers/6351267"}],"claims":[{"public_id":"cl_c9dd1ea4d9210cb4d05b482e138ada3f","text":"Adverse event rates did not differ across treatment groups, and adjudicated cardiovascular event rates were similarly low.","corpus_id":6351267,"url":"https://sah.borca.ai/claims/cl_c9dd1ea4d9210cb4d05b482e138ada3f"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_b4c7d87f2675e804735f74e2795a33e3","url":"https://sah.borca.ai/concepts/co_b4c7d87f2675e804735f74e2795a33e3"}